A new study published in the journal Nature reports results of the first-in-human phase 1 clinical trials of a novel ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel ...

Use of the anti-CD19 CAR T-cell therapy obecabtagene autoleucel (obe-cel; Aucatzyl) resulted in durable remissions among ...

The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...

Engineered receptors could lead to more precisely targeted, effective cancer therapies with fewer side effects than existing ...

Roche RHHBY announced that it will acquire clinical-stage biopharmaceutical company Poseida Therapeutics, Inc. PSTX for $9 ...

A small trial used designer CAR T cells to reboot the immune systems of patients with three autoimmune diseases, but it's ...

T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...

A $2.3 million National Cancer Institute grant will fund a University of Cincinnati Cancer Center study to develop a new ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...